Changes in gene expression associated with stable drug and radiation resistance in small cell lung cancer cells are similar to those caused by a single X-ray dose

Radiation Research

Volumn 161, Issue 5, 2004, Pages 495-503

  Henness, Sheridan ^a   Davey, Mary W ^b   Harvie, Rozelle M ^a   Banyer, Joanne ^c   Wasinger, Valerie ^d   Corthals, Garry ^d   Davey, Ross A ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^c Biology and Environment   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DAUNORUBICIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; TUMOR PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE; CELL LINE; CELL METABOLISM; CELL STRAIN H69; CYTOSKELETON; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; NORTHERN BLOTTING; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; PROTEIN SYNTHESIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; SUPPRESSION SUBTRACTIVE HYBRIDIZATION; X RAY; COMPARATIVE STUDY; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; RADIATION EXPOSURE; RADIATION RESPONSE; SMALL CELL CARCINOMA; TUMOR CELL LINE;

CARCINOMA, SMALL CELL; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; RADIATION DOSAGE; RADIATION TOLERANCE; X-RAYS;

EID: 2942579657     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR3165     Document Type: Article

References (23)

1. A. T. Turrisi and C. A. Sherman, The treatment of limited small cell lung cancer: A report of the progress made and future prospects. Eur. J. Cancer 38, 279-291 (2002).
2. N. Jain, Y. M. Lam, J. Pym and B. G. Campling, Mechanisms of resistance of human small cell lung cancer lines selected in vp-16 and cisplatin. Cancer 77, 1797-1808 (1996).
3. P. B. Jensen, B. Holm, M. Sorensen, I. J. Christensen and M. Sehested, In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines-preclinical identification of suitable drug partners to Taxotere, Taxol, topotecan and gemcitabine. Br. J. Cancer 75, 869-877 (1997).
4. T. Moritaka, K. Kiura, H. Ueoka, M. Tabata, Y. Segawa, T. Shibayama, N. Takigawa, T. Ohnoshi and M. Harada, Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids. Anticancer Res. 18, 927-933 (1998).
5. S. P. Cole, G. Bhardwaj, J. H. Gerlach, J. E. Mackie, C. E. Grant, K. C. Almquist, A. J. Stewart, E. U. Kurz, A. M. Duncan and R. G. Deeley, Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258, 1650-1654 (1992).
6. G. M. Su, M. W. Davey and R. A. Davey, Induction of broad drug resistance in small cell lung cancer cells and its reversal by paclitaxel. Int. J. Cancer 76, 702-708 (1998).
7. C. D. Evans, S. E. Mirski, M. K. Danks and S. P. Cole, Reduced levels of topoisomerase II alpha and II beta in a multidrug-resistant lung-cancer cell line. Cancer Chemother. Pharmacol. 34, 242-248 (1994).
8. L. A. Doyle, D. D. Ross, J. V. Ordonez, W. Yang, Y. Gao, Y. Tong, C. P. Belani and J. C. Gutheil, An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein. Br. J. Cancer 72, 535-542 (1995).
9. U. A. Sartorius and P. H. Krammer, Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int. J. Cancer 97, 584-592 (2002).
10. U. Zangemeister-Wittke, T. Schenker, G. H. Luedke and R. A. Stahel, Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br. J. Cancer 78, 1035-1042 (1998).
11. K. Gemba, H. Ueoka, K. Kiura, M. Tabata and M. Harada, Immunohistochemical detection of mutant p53 protein in small-cell lung cancer: Relationship to treatment outcome. Lung Cancer 29, 23-31 (2000).
12. S. Henness, M. W. Davey, R. M. Harvie and R. A. Davey, Fractionated irradiation of H69 small cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2 and topoisomerase II expression. Int. J. Radiat. Oncol. Biol. Phys. 54, 895-902 (2002).
13. L. Diatchenko, Y. F. Lau, A. P. Campbell, A. Chenchik, F. Moqadam, B. Huang, S. Lukyanov, K. Lukyanov, N. Gurskaya and P. D. Siebert, Suppression subtractive hybridization: A method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc. Natl. Acad. Sci. USA 93, 6025-6030 (1996).
14. P. Chomcyznski and N. Sacchi, Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156-159 (1987).
15. G. M. O'Neill, G. B. Peters, R. M. Harvie, H. B. Mackenzie, S. Henness and R. A. Davey, Amplification and expression of the ABC transporters ARA and MRP in a series of multidrug-resistant leukaemia cell sublines. Br. J. Cancer 77, 2076-2080 (1998).
16. J. I. Garrels and B. R. Franza, Jr., The REF52 protein database. Methods of database construction and analysis using the QUEST system and characterizations of protein patterns from proliferating and quiescent REF52 cells. J. Biol. Chem. 264, 5283-5298 (1989).
17. A. Schevchenko, M. Wilm, O. Vorm and M. Mann, Mass spectrometric sequencing of proteins from silver-stained polyacrylamide gels. Anal. Chem. 68, 850-858 (1996).
18. D. L. Rothemund, V. L. Locke, A. Liew, T. M. Thomas, V. Wasinger and D. B. Rylatt, Depletion of the highly abundant protein albumin from human plasma using the Gradiflow. Proteomics 3, 279-287 (2003).
19. M. E. Harper, A. Antoniou, E. Villalobos-Menuey, A. Russo, R. Trauger, M. Vendemelio, A. George, R. Bartholomew, D. Carlo and M. K. Newell, Characterization of a novel metabolic strategy used by drug-resistant tumor cells. FASEB J. 16, 1550-1557 (2002).
20. L. Zhang, R. E. Cilley and M. R. Chinoy, Suppression subtractive hybridization to identify gene expressions in variant and classic small cell lung cancer cell lines. J. Surg. Res. 93, 108-119 (2000).
21. S. P. Cole, H. F. Downes, S. E. Mirski and D. J. Clements, Alterations in glutathione and glutathione-related enzymes in a multidrug-resistant small cell lung cancer cell line. Mol. Pharmacol. 37, 192-197 (1990).
22. J. W. Chang, H. B. Jeon, J. H. Lee, J. S. Yoo, J. S. Chun, J. H. Kim and Y. L. Yoo, Augmented expression of peroxiredoxin I in lung cancer. Biochem. Biophys. Res. Commun. 289, 507-512 (2001).
23. V. L. Kinnula, S. Lehtonen, R. Sormunen, R. Kaarteenaho-Wiik, S. W. Kang, S. G. Rhee and Y. Soini, Overexpression of peroxiredoxins I, II, HI, V, and VI in malignant mesothelioma. J. Pathol. 196, 316-323 (2002).